食管癌患者放疗中期18F-FDG PET/CT的预后价值
该回顾性研究纳入21例接受放疗的食管癌患者,在放疗11次后行分次间18F-FDG PET/CT,计算SUVmax、SUVmean、MTV和TLG及其相对变化。中位随访13个月,1年总生存率和无进展生存率分别为79.0%和34.4%。ΔMTV与局部区域复发显著相关(p=0.03),ΔSUVmean与远处转移风险相关(p=0.02)。
要点
- 放疗11次后ΔMTV与局部区域复发显著相关(p=0.03)。
- ΔSUVmean与远处转移风险相关(p=0.02)。
- ΔMTV阈值1.14预测局部区域复发的灵敏度60%、特异度94%、准确率86%。
核心结论
- 放疗期间肿瘤代谢变化可用于预测食管癌患者的治疗反应、复发和预后。
研究设计与样本
- 回顾性分析21例接受放疗的食管癌患者,均行治疗前18F-FDG PET/CT(PET1)和放疗11次后分次间18F-FDG PET/CT(PET2),中位剂量23.1 Gy,每次2.1 Gy。
主要发现
- 中位随访13个月,1年总生存率和无进展生存率分别为79.0%和34.4%。
- 4例患者发生局部区域复发,8例发生远处转移。
- 1年无局部区域复发率为76.9%,无远处转移率为60.6%。
- ΔMTV与局部区域复发显著相关(p=0.03),ΔSUVmean与远处转移风险相关(p=0.02)。
关键数值与推荐
- ΔMTV阈值1.14预测局部区域复发的灵敏度60%、特异度94%、准确率86%。
- ΔSUVmean下降35%阈值预测远处转移的灵敏度67%、特异度83%、准确率76%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To identify whether early metabolic responses as determined using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) during radiotherapy (RT) predict outcomes in patients with esophageal cancer. METHODS: Twenty-one patients with esophageal cancer who received pre-treatment 18F-FDG PET/CT (PET1) and inter-fractional 18F-FDG PET/CT (PET2) after 11 fractions of RT (median 23.1 Gy, 2.1 Gy per fraction) were retrospectively reviewed. The region of interest for each calculation was delineated using "PET Edge". We calculated PET parameters including maximum and mean standardized uptake values (SUVmax and SUVmean, respectively), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). The relative changes (%) were calculated using the logarithmically transformed parameter values for the PET1 and PET2 scans. Multivariate analysis of locoregional recurrence and distant failures were performed using Cox regression analysis. After identifying statistically significant PET parameters for discriminating responders from non-responders, receiver operating characteristics curve analyses were used to assess the potentials of the studied PET parameters. RESULTS: After a median follow-up of 13 months, the 1-year overall and progression-free survival rates were 79.0% and 34.4%, respectively. Four patients developed locoregional recurrences (LRRs) and 8 had distant metastases (DMs). The 1-year overall LRR-free rate was 76.9% while the DM-free rate was 60.6%. The relative changes in MTV (ΔMTV) were significantly associated with LRR (p = 0.03). Conversely, the relative changes in SUVmean (ΔSUVmean) were associated with the risk of DM (p = 0.02). An ΔMTV threshold of 1.14 yielded a sensitivity of 60%, specificity of 94%, and an accuracy of 86% for predicting an LRR. Additionally, a ΔSUVmean threshold of a 35% decrease yielded a sensitivity of 67%, specificity of 83%, and accuracy of 76% for the prediction DM. TRIAL REGISTRATION: Retrospectively registered. CONCLUSIONS: Changes in tumor metabolism during RT could be used to predict treatment responses, recurrences, and prognoses in patients with esophageal cancer.
引用
- Kim N, Cho H, Yun M, et al. Prognostic values of mid-radiotherapy 18F-FDG PET/CT in patients with esophageal cancer. Radiat Oncol. 2019. PMID: 30717809. doi:10.1186/s13014-019-1232-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。